Preclinical News and Research

RSS
Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex second quarter net loss decreases to $5.3 million

Unigene second quarter revenue decreases to $2.5 million

Unigene second quarter revenue decreases to $2.5 million

Intralipid may protect patients from heart attacks

Intralipid may protect patients from heart attacks

Idera second quarter net loss increases to $6.3 million

Idera second quarter net loss increases to $6.3 million

Novel studies explore new targets to prevent spread of breast cancer

Novel studies explore new targets to prevent spread of breast cancer

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst second quarter total revenues decrease to $3.7 million

Study: Chronic mitral valve disease similar in humans and dogs

Study: Chronic mitral valve disease similar in humans and dogs

Avaxia receives BARDA contract to develop new radiation mitigation drug

Avaxia receives BARDA contract to develop new radiation mitigation drug

Hopkins stem cell research to examine how gene variants cause blood clotting disorders

Hopkins stem cell research to examine how gene variants cause blood clotting disorders

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

Celldex second quarter net loss increases to $10.2 million

Celldex second quarter net loss increases to $10.2 million

Bruker second quarter revenue increases 33% y-o-y to $401.2 million

Bruker second quarter revenue increases 33% y-o-y to $401.2 million

Zalicus second quarter revenue decreases to $1.8 million

Zalicus second quarter revenue decreases to $1.8 million

GSK, NPS enter agreement to evaluate ronacaleret in new indications

GSK, NPS enter agreement to evaluate ronacaleret in new indications

Scientists look to create blood platelets from stem cells to study genetics of blood clotting disorders

Scientists look to create blood platelets from stem cells to study genetics of blood clotting disorders

ARIAD reports $47.8 million net loss for second quarter 2011

ARIAD reports $47.8 million net loss for second quarter 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam second quarter revenue decreases to $20.6 million

Femta files IND with FDA for FM101 monoclonal antibody against RA

Femta files IND with FDA for FM101 monoclonal antibody against RA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.